Freenome
Freenome makes SimpleScreen CRC, the second FDA-approved blood test for colorectal cancer screening (July 2026), commercialised by Abbott.
FDA approved SimpleScreen CRC on 24 July 2026 for average-risk adults 45+ based on PREEMPT CRC (>48,000 participants; ~80% CRC sensitivity, ~90% specificity). Freenome listed via a $330M SPAC merger (2025-26); Abbott holds US commercial rights and paid a $100M approval milestone; launch expected autumn 2026.
Pages like this
not linked directly; found by shared links- IdeaMandatory interval-cancer audit for every blood-based screening test
Shares Shield, Multi-cancer early detection (MCED), Most lethal cancers are found late, Liquid biopsy (ctDNA).
- CompanyHarbinger Health
Shares DNA methylation profiling, Multi-cancer early detection (MCED), Most lethal cancers are found late.
- IdeaA urine DNA test to decide who with blood in the urine needs a camera test
Shares DNA methylation profiling, Most lethal cancers are found late, Liquid biopsy (ctDNA).
- InstitutionPrince of Wales Hospital / Chinese University of Hong Kong
Shares DNA methylation profiling, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA), Colorectal cancer.
- IdeaCheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests
Shares Multi-cancer early detection (MCED), Most lethal cancers are found late, Liquid biopsy (ctDNA).
- IdeaBlood-based HCC surveillance to replace six-monthly ultrasound
Shares DNA methylation profiling, Multi-cancer early detection (MCED), Most lethal cancers are found late.
- IdeaA ten-dollar blood test for the five cancers that kill most people in poorer countries
Shares DNA methylation profiling, Multi-cancer early detection (MCED), Most lethal cancers are found late.
- IdeaNon-endoscopic screening for Barrett's oesophagus and early adenocarcinoma
Shares DNA methylation profiling, Multi-cancer early detection (MCED), Most lethal cancers are found late.